382150 — OncoCross Co Income Statement
0.000.00%
Last trade - 00:00- KR₩150bn
- KR₩130bn
- KR₩1bn
Annual income statement for OncoCross Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 150 | 91.5 | 1,072 |
| Cost of Revenue | |||
| Gross Profit | 34.6 | 4.51 | 722 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 10,569 | 6,052 | 8,037 |
| Operating Profit | -10,419 | -5,960 | -6,965 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -10,204 | -4,106 | -6,483 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -10,204 | -4,214 | -6,483 |
| Net Income Before Extraordinary Items | |||
| Net Income | -10,204 | -4,214 | -6,483 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -10,204 | -4,214 | -6,483 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -824 | -402 | -619 |
| Dividends per Share |